SGMT Sagimet Biosciences Inc.
Sagimet Biosciences Inc. (SGMT) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 86% planned / 14% discretionary
Largest single sale: $3.6M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Kemble George | Director | Sell 10b5-1 | 350,987 | $10.23 | $3.6M | 62,161 −85% of holding | |
| Kemble George | Director | Sell 10b5-1 | 20,206 | $9.95 | $201.1K | 62,161 −24.5% of holding | |
| Happel David | President & CEO | Sell | 64,051 | $7.76 | $497.1K | 741,570 −8% of holding | |
| Kemble George | Director | Sell 10b5-1 | 18,844 | $7.46 | $140.5K | 62,161 −23.3% of holding | |
| Rozek Elizabeth | Chief Legal & Admin. Officer | Sell | 10,545 | $7.76 | $81.8K | 224,414 −4.5% of holding | |
| Happel David | President & CEO | Sell | 12,101 | $5.36 | $64.9K | 677,621 −1.8% of holding | |
| Martins Eduardo Bruno | Chief Medical Officer | Sell | 3,640 | $5.36 | $19.5K | 103,296 −3.4% of holding | |
| Rozek Elizabeth | Chief Legal & Admin. Officer | Sell | 2,622 | $5.36 | $14.1K | 190,959 −1.4% of holding | |
| Chauche Thierry | Chief Financial Officer | Sell | 1,312 | $5.36 | $7.0K | 15,688 −7.7% of holding | |
| Kemble George | Executive Chairman | Sell 10b5-1 | 37,688 | $7.69 | $290.0K | 81,005 −31.8% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.